 SEATTLE, Oct. 01, 2021 GLOBE NEWSWIRE -- Neoleukin Therapeutics, Inc., Neoleukin NASDAQ:NLTX, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancers 36th Annual Meeting SITC 2021 taking place November 10-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. 